Saline whole-blood impedance aggregometry for detection of heparin-independent platelet-activating anti–platelet factor 4 antibodies
American Journal of Clinical Pathology · 03.09.2026 · 166 (3)
DOI: 10.1093/ajcp/aqag100 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 10.09.2026. Verfasst von Jing Jin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Special Coagulation, Clinical Laboratory, Stanford Hospital and Clinics, Stanford, CA, United States. Hauptthemen laut MEDLINE: Platelet Factor 4, Heparin, Thrombocytopenia, Autoantibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Objectives
This study evaluates the practice of incorporating a saline testing condition into the heparin-induced thrombocytopenia (HIT) functional assay using whole-blood impedance aggregometry (WBIA) to identify a subgroup of highly pathogenic anti–platelet factor 4 (PF4) antibodies with heparin-independent platelet-activating properties.
Methods
From 2023 to 2025, we analyzed 150 evaluable patients (65 WBIA Negative, 85 WBIA Positive). Positive cases were subdivided into Classic-Positive (low-dose heparin positive only; n = 46) and Saline-Positive (positive under both low-dose heparin and saline; n = 35). The diagnosis of clinical HIT by hematologists was used as reference. PF4/IgG was measured by chemiluminescent immunoassay; WBIA was performed with low-dose heparin, high-dose heparin, and saline; and available serotonin release assay (SRA) results were analyzed.
Results
Saline-Positive patients exhibited significantly higher incidences of HIT-associated thrombosis (89% vs 54%, P = .005), delayed-onset HIT (23% vs 0%, P = .001), refractory HIT (40% vs 7%, P < .001), spontaneous HIT (14% vs 0%, P = .013), and more venous thromboembolism (pulmonary embolism and deep vein thrombosis, P < .05) compared with Classic-Positive patients. All 35 Saline-Positive cases were classified as autoimmune HIT (aHIT). The spontaneous HIT subset (n = 5) displayed a distinct pattern of low-titer anti-PF4 antibodies discordant with strong saline-WBIA reactivity and a high SRA false-negative rate (57.1%). High-dose intravenous immunoglobulin neutralized saline positivity in real time.
Conclusions
Saline-positivity in WBIA identifies a heparin-independent aHIT phenotype with higher pathogenicity and thrombotic risk. This rapid saline protocol addresses diagnostic gaps where standard 2-condition SRA protocols may fail, offering a practical tool to identify high-pathogenic anti-PF4 antibodies and guide clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Special Coagulation, Clinical Laboratory, Stanford Hospital and Clinics, Stanford, CA, United States.
- Department of Medical Education, Dell Medical School, University of Texas at Austin, Austin, TX, United States.
- Department of Pathology, School of Medicine, Stanford University, Stanford, CA, United States.
- Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
Zitieren
APA
Jin, J., Yang, L. M., Zhang, J., Patel, K., & Zehnder, J. L. (2026). Saline whole-blood impedance aggregometry for detection of heparin-independent platelet-activating anti–platelet factor 4 antibodies. American Journal of Clinical Pathology, 166(3). https://doi.org/10.1093/ajcp/aqag100
Vancouver
Jin J, Yang LM, Zhang J, Patel K, Zehnder JL. Saline whole-blood impedance aggregometry for detection of heparin-independent platelet-activating anti–platelet factor 4 antibodies. American Journal of Clinical Pathology. 2026;166(3). doi:10.1093/ajcp/aqag100
BibTeX
@article{Jin2026,
author = {Jin, Jing and Yang, Lu M and Zhang, Juan and Patel, Krinaben and Zehnder, James L},
title = {Saline whole-blood impedance aggregometry for detection of heparin-independent platelet-activating anti–platelet factor 4 antibodies},
journal = {American Journal of Clinical Pathology},
year = {2026},
volume = {166},
number = {3},
doi = {10.1093/ajcp/aqag100}
}
EUVIMED